Skip to main content

Table 2 Estimated hazard ratiosa from the multivariable Cox proportional model on event-free survival and hazard of relapse in patients of the study cohort

From: Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group

Variable

Event

Relapse

Hazard Ratio (95% CIa)

P(X2)

Hazard Ratio (95% CIa)

P(X2)

Bilirubin CTC grades 3-4b

1.67 (1.21-2.30)

0.002

1.49 (1.00-2.21)

0.049

ALT/AST CTC grade 4c

0.88 (0.56-1.38)

0.575

1.02 (0.61-1.69)

0.955

MRD standard riskd

0.49 (0.34-0.69)

< 0.001

0.51 (0.34-0.77)

0.001

MRD high riskd

4.07 (2.87-5.78)

< 0.001

4.17 (2.72-6.38)

< 0.001

Slow early responsee

3.32 (2.19-5.03)

< 0.001

4.21 (2.66-6.66)

< 0.001

Poor prednisone responsef

1.12 (0.77-1.64)

0.556

0.91 (0.57-1.45)

0.686

Initial WBC count ≥100,000g

1.39 (0.96-2.02)

0.078

1.50 (0.96-2.32)

0.074

  1. a Hazard ratios (HR) are given as indicated with the corresponding 95% confidence intervals (95% CI), all patients of the study cohort with complete information were included in this analyses (n = 1518 of 1547)
  2. b HR compared patients with high bilirubin serum levels ≥ grade 3 of the Common Toxicity Criteria of the National Cancer Institute version 2 (CTC) with patients presenting normal levels or moderate levels
  3. c HR compared patients with severe alanine (ALT) or aspartate (AST) transaminase activity levels ≥ CTC grade 4 with patients presenting normal or moderately elevated levels
  4. d Minimal residual disease (MRD) standard risk, negative on treatment days 33 and 78; MRD high risk, leukemic cell load ≥5 × 10-4 on treatment day 78; all other results MRD intermediate risk. HR compared with the other respective MRD groups
  5. e MRD ≥5 × 10-4 on treatment day 33 and positivity of < 5 × 10-4 on treatment day 78. HR compared with MRD intermediate-risk patients with no slow early response
  6. f Leukemic blasts ≥1000/μL in the peripheral blood on treatment day 8. HR compared with patients with ≥1000/μL leukemic blasts
  7. g HR compared patients with a white blood cell (WBC) count at diagnosis ≥100,000 /μL with patients presenting WBC counts < 100,000 /μL